Herbalife Ltd. (NYSE: HLF) reported financial results for the second quarter ended June 30, 2026. Net sales reached $1.3 billion, up 5.4% from the same period last year and at the top of the company’s guidance range. On a constant currency basis, sales rose 5.8% year-over-year and exceeded guidance. This marked the fourth consecutive quarter of year-over-year net sales growth on both a reported and constant currency basis.
Net loss attributable to Herbalife was $26.3 million. The figure includes a $94.6 million loss on extinguishment of debt following a successful April 2026 refinancing. Adjusted net income stood at $53.3 million.
Adjusted EBITDA came in at $166.6 million, toward the upper end of guidance. On a constant currency basis, adjusted EBITDA reached $174.4 million and exceeded expectations. Credit Agreement EBITDA was $190.7 million. Diluted loss per share was $0.25, while adjusted diluted EPS was $0.51.
Year-to-date net cash provided by operating activities totaled $146.7 million. Capital expenditures were $22.2 million.
CEO Stephan Gratziani highlighted the quarter’s strategic milestone. “This quarter marks an important milestone in the execution of our personalized nutrition strategy with the launch of Bioniq in Europe and the United States. We are bringing our vision to life and expanding the value we create for customers.”
The company launched Bioniq GO, its next-generation personalized product. The offering matches customers to one of forty formulas and rolled out across eleven EMEA markets in June and North America in July. Additional markets are planned later in 2026. Subscription options for automatic monthly deliveries are now available in the newly launched European markets.
Herbalife also introduced two new products under its healthy lifespan brand, Life I/O: Helio, a daily all-in-one super shake, and Activate Energy, an exogenous ketones product stemming from the Pruvit acquisition.
At the North America Extravaganza, the company released a significant update to its Pro2col platform as part of an extended beta program. The update features a new user experience, enhanced tools, and blood-test diagnostic integration. An early beta of an at-home blood biomarker diagnostic also began with select North American distributors in July.
John DeSimone will retire as Chief Financial Officer effective December 31, 2026. Scott Schaefer has been named his successor and will assume the role on January 1, 2027, as part of a planned transition.
Herbalife provided third-quarter 2026 guidance and revised its full-year outlook. The company tightened the net sales range and narrowed adjusted EBITDA guidance to $670 million–$690 million from the prior $675 million–$705 million range. The adjustment primarily reflects foreign exchange headwinds, while constant currency guidance was raised.
CFO John DeSimone noted that second-quarter net sales and EBITDA results landed at the high end of previous guidance. He added that recent U.S. dollar strength has created additional FX pressure on the reported outlook for the second half of the year, though the constant currency view remains consistent with earlier expectations.
Â
There are no reviews yet. Be the first one to write one.
